Statement: Patients with HER2 + breast cancer stage 1-4  are eligible for both the primary trial and the secondary trial.
Primary_evidence: Inclusion Criteria:   Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer   Participants who are undergoing breast cancer surgery with lumpectomy or mastectomy   Participants with planned axillary sentinel node biopsy procedure Exclusion Criteria:   Participants with cancer > 3 cm   Participants with clinically positive nodes   Participants with prior surgery for breast cancer in the index breast   Participants who have had bilateral breast surgeries   Thyroid dysfunction   Hypersensitivity to iodine   Hepatic insufficiency   Renal insufficiency
Secondary_evidence: Inclusion Criteria:   Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer   Prior use of Herceptin (trastuzumab), and a taxane   Adequate cardiac and renal function Exclusion Criteria:   More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) [Tyverb]   Bone as the only site of disease   Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)   Significant gastrointestinal disorder with diarrhea as major symptom